3 results
Approved WMOCompleted
This study will evaluate the efficacy and safety of gantenerumab compared with placebo in patients with early (prodromal to mild) Alzheimer's disease (AD).
Not approvedWill not start
The primary objective of this secondary prevention study is to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of gantenerumab, an anti-amyloid antibody, in amyloid-positive, cognitively unimpaired participants at risk for or…
Approved WMOPending
Primary objective: To explore the effect on volume of keloid tissue (mm3), measured by 3D-camera, after three consecutive treatments with electronic jet injector assisted bleomycin delivery, compared with placebo in a split-lesion design.Secondary…